



WEEKLY WRAP-UP

30TH JUNE - 04TH JULY 2025

PROGRESSIVE[®]
Your Progress Our Priority...

Equities | Derivatives | Commodities | Currency | PMS | Depository | Mutual Funds | NBFC | e-Broking



HIGHLIGHTS OF THE WEEK

30 June 2025-04 July 2025

DOMESTIC:

- NTPC Renewable Energy fully commissions 220MW Shajapur Solar project
- Tata Steel aims to have 20% diversity workforce by 2028
- Kalpataru Projects International bags new orders worth Rs989cr
- L&T sets up new arm to develop green hydrogen projects
- Sigachi temporarily suspends production at Hyd. unit for 90 days after fire incident
- Delhivery gets Rs1.36cr penalty order from Income Tax department
- Hindustan Copper, Coal India sign MoU for critical minerals
- Apollo Hospitals to hive-off pharmacy, digital health businesses
- NCC bags Rs16,915mn building contracts from state agencies, private firm
- NMDC cuts rates of iron ore lump by Rs600/tonne, fines by Rs500 per tonne
- NBCC bags Rs3,550mn PMC order for zoo infrastructure project in Nagpur
- Tata Power ordered to pay USD490mn to Kleros in partial arbitration award
- RITES bags multiple orders from domestic and international entities
- Max Financial reports cyber threat at unit; initiates security check
- SBI marks Reliance Communications as fraud account; company says order ex-parte
- Paras Defence subsidiary bags Rs220mn French order for indigenous anti-drone system
- JSW Energy's green energy arm inks battery storage deal in Rajasthan
- Lupin carves out consumer healthcare biz into WoS
- Dr. Reddy's expects US sales dip in FY26, aims for resilience via scale-up
- ONGC signs pact with Japan's Mitsui for ethane carriers
- Carlye may sell up to 10% stake in Piramal Pharma via block deals
- CCI approves Coromandel Intl's Rs8200mn acquisition of majority stake in NACL
- Godrej Industries' chemicals biz announces over Rs750cr investment for capacity expansion
- MOIL reports record 5 lakh tonnes manganese ore production in Q1
- PVR INOX plans to add 200 screens in 2 years: ED Sanjeev Kumar Bijli
- HC restrains Patanjali from airing ads criticising Dabur Chyawanprash
- IHCL unveils Taj Damdama report as it eyes double-digit growth in FY26
- Marico estimates low-twenties percentage quarterly revenue growth

ECONOMY:

- June GST collection drops below Rs21k-cr mark
- MF funding to NBFCs hits record Rs2.77trn in May 2025: CareEdge
- India conveys concerns to US Senator on Russian oil 'tariff'

INDUSTRY:

- Crude oil prices back at USD67/barrel, likely to remain stable: Minister Puri
- Coal India production drops by 8.5% in June
- India initiates anti-dumping probe into import of multi-layer paperboard from Indonesia

HIGHLIGHTS OF THE WEEK

30 June 2025-04 July 2025

COVERAGE NEWS:

Torrent Pharmaceuticals Ltd: The company has signed definitive agreements with KKR to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals. Torrent will acquire 46.39% equity for Rs11,917cr, followed by a mandatory open offer to purchase up to an additional 26% of JB Pharma shares from public shareholders at Rs1,639.18 per share. Torrent also intends to acquire up to 2.80% of equity from certain JB Pharma employees.

Texmaco Rail & Engineering Ltd: The company has secured an order of approx. Rs277mn from South Western Railway for TRD maintenance & breakdown activities.

Timken India Ltd: The company has informed that the commercial production from new manufacturing facility at Bharuch has commenced w.e.f. 30th June, 2025.

Bannari Amman Spinning Mills Ltd: The company has approved raising upto Rs149.9mn by issuing 41,66,660 convertible warrants on a preferential basis at Rs36 per warrant (including a premium of Rs31) of FV of Rs5 each.

Nesco Ltd: The company had earlier indicated of receiving the IOD for Tower 2 and thereby the board has approved a capex of upto Rs3,500cr for development of Tower 2 in IT Park to be utilised over a period of six years subject to receipt of timely statutory approvals. The funding for this project shall primarily be done from internal accruals.

KSB Ltd: The company has received an order for the supply of 15 sets of main boiler feed pumps (along with booster pumps, motors, and accessories) from L&T for NTPC's supercritical power plant projects. The order is to be completed between 20-28 months with staggered payments based on milestones as per the contract.

Container Corporation of India Ltd: The company has introduced specialized tank containers for the first time to facilitate the transportation of bulk cement in loose form.

Lloyds Engineering Works Ltd: The Board has approved the acquisition of 13,75,000 equity shares with Techno Industries Pvt. Ltd (TIPL) for a consideration of approx. Rs250mn amounting to 11% of acquisition of shares in TIPL. Pursuant to this, the company shall hold an aggregate stake of 88% in TIPL.

Zen Technologies Ltd: The company has completed the acquisition of 2,06,518 equity shares of FV of Rs10 each and 4,00,000 numbers of 6% CCDs from an existing CCD holder, issued by TISA Aerospace Private Limited, resulting in the company holding a 76% stake in TISA, making it a subsidiary. Following the conversion of CCDs, TISA has allotted 3,35,806 equity shares to the company.

GMM Pfaudler Ltd: The company through its WoS Pfaudler Ltda. in Brazil, has signed an agreement to acquire 100% equity of SEMCO Tecnologia em Processos Ltda. for a cash consideration of USD18.5mn, with the transaction expected to close in Q2FY26.

Hind Rectifiers Ltd: (i) The company has secured an order worth Rs1270mn and Rs1010mn from the Indian Railways and is expected to be executed in FY27 and between FY26-FY27 respectively, (ii) The company has secured orders aggregating Rs2840mn during June 2025 and thus the pending order book as of 1st July, 2025 stood at Rs10,250mn.

Alembic Pharmaceuticals Ltd: (i) The company has received USFDA final approval for Doxorubicin Hydrochloride Liposome Injection, 20mg/10mL (2mg/mL) and 50mg/25mL (2mg/mL) single-dose vials. As per IQVIA, the injection has an estimated market size of USD29mn for twelve months ending March 2025, (ii) Alembic Pharmaceuticals Inc. (WoS of Alembic Pharmaceuticals) has acquired Utility Therapeutics Ltd for approx. USD12mn in a staggered manner depending on milestones achieved.

Magna Electro Castings Ltd: The company has informed of commencement of commercial production of third moulding line. With this, the total installed moulding capacity now stands at 2000MT per month.

Aurobindo Pharma Ltd: (i) Aurobindo's wholly owned stepdown subsidiary Lyfius Pharma Pvt. Ltd has received a consent to operate (CTO) approval from the Andhra Pradesh Pollution Control Board (APPCB) for its Penicillin-G manufacturing facility, at Kakinada and the production has re-started with immediate effect from 29th June, 2025, (ii) Aurobindo's wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o., has obtained marketing authorization from the European Commission for Dazublys, its trastuzumab biosimilar version.

Sandhar Technologies Ltd: The company has executed a sale agreement with Sandhar Engineering Pvt. Ltd (WoS) for the entire plant and machinery of Sandhar Technologies Ltd (HR)-Unit-III for a consideration of approx. Rs190.1mn.

HIGHLIGHTS OF THE WEEK

30 June 2025-04 July 2025

COVERAGE NEWS:

Patel Engineering Ltd: The Board has approved the issuance of non-convertible debentures upto Rs2000mn in one or more tranches during the FY through private placement basis.

GMM Pfaudler Ltd: The company through its WoS Pfaudler Ltda. in Brazil, has signed an agreement to acquire 100% equity of SEMCO Tecnologia em Processos Ltda. for a cash consideration of USD18.5mn, with the transaction expected to close in Q2FY26.

Indegene Ltd: The company has announced a strategic long-term partnership with Foundation for Advancing Science and Technology (FAST) to scale up India's biotech ecosystem.

J.B. Chemicals & Pharmaceuticals Ltd: The Board has approved the change in registered office of the company from Mumbai to Ahmedabad. The said change is subject to the approval of the members of the company and receipt of requisite statutory and regulatory approvals.

The Week That Went By:

With a lacklustre performance, the Index compounded its losses for most of the time and eventually settled the week at 25,461 with a loss of 176.80 points. Among the sectors, Pharma was the top performer, followed by PSU Banks, while Realty corrected over 2%. Mid and Smallcaps managed to outperform Nifty50 with gains of 0.49% and 0.30%, respectively.

Nifty50=25,461.00

Sensex30=83,432.89

Nifty Midcap 100=59,677.75

Nifty Smallcap100=19,033.05

HIGHLIGHTS OF THE WEEK

30 June 2025-04 July 2025

NIFTY (WEEKLY)



BANK NIFTY (WEEKLY)



MARKET OUTLOOK

On the daily chart, **Nifty50** appears to be forming a Bullish Flag and Pole pattern, and a decisive move above the 25,570 mark would confirm a breakout, potentially leading to further upside. The immediate support is placed at 25,330, while resistance stands at 25,600. Despite trading at record highs, **BankNifty** is showing signs of a potential bearish divergence, although not yet confirmed. A sustained move above 57,600 would negate the bearish setup, while a breakdown below 56,640 could trigger a decline toward 56,300. The key support and resistance levels for BankNifty are placed at 56,850 and 57,200, respectively. Within the **Energy sector**, we continue to remain positive on **OMCs (BPCL, HPCL, and IOC)** and they have already confirmed breakouts. The **IT sector** remains range-bound in an extremely narrow band. We believe that soon a breakout will occur to provide a directional trend. The **Pharma sector** is pointing towards a trend reversal, with a breakout from an **Inverted Head and Shoulder pattern (Aurobindo Pharma-Falling Channel Breakout, and Glenmark Pharma & Laurus Labs-Rounding Bottom Breakout)**. Meanwhile, **Metal and PSU Banking** sectors are on the verge of important pattern breakouts, and a strong rally could follow once confirmed. In the lower timeframe, the **Realty sector** shows signs of a trend reversal, with a bullish pattern formation coupled with a hidden bullish divergence at the rounding bottom breakout zone, indicating a completed pullback. However, a confirmatory move is essential.


HIGHLIGHTS OF THE WEEK

30 June 2025-04 July 2025

NIFTY 50 COMPONENTS (WEEKLY PERFORMANCE)

Adani Enterprises	(1.73%)	HDFC Life	(2.53%)	Reliance	0.93%
Adani Ports	(1.01%)	Hero Motocorp	0.41%	SBI Life	(2.53%)
Apollo Hospital	3.28%	Hindalco	0.14%	SBIN	0.83%
Asian Paints	2.79%	HUL	1.44%	ShriRam Finance	(3.00%)
Axis Bank	(3.91%)	ICICI Bank	(1.02%)	Sun Pharma	(0.95%)
Bajaj Auto	(0.47%)	IndusInd Bank	(0.67%)	Tata Consumer	(2.81%)
Bajaj Finserv	(2.16%)	INFY	1.78%	Tata Motors	0.07%
Bajaj Finance	(1.91%)	ITC	(1.74%)	Tata Steel	1.12%
BEL	2.67%	JioFin	0.12%	TCS	(0.73%)
Bharti Airtel	(0.08%)	JSW Steel	1.17%	Tech Mahindra	(1.55%)
Cipla	0.37%	Kotak Bank	(3.23%)	TITAN	0.40%
Coal India	(2.43%)	LT	(2.28%)	Trent	(9.44%)
Dr. Reddy's Labs	0.58%	M&M	(1.80%)	Ultratech	2.17%
Eicher Motors	(0.08%)	Maruti	(0.16%)	Wipro	1.53%
Eternal	(0.69%)	Nestle India	(2.70%)		
Grasim	(2.11%)	NTPC	0.00%		
HCL Tech	(0.16%)	ONGC	0.33%		
HDFC Bank	(0.93%)	PowerGrid	(1.44%)		

SECTORAL PERFORMANCE



HIGHLIGHTS OF THE WEEK

30 June 2025-04 July 2025

SECTORAL GAINER



The **Pharma sector** soared over 2% and outperformed the Benchmark Index. Among the components, **Natco Pharma (+13.13%)**, **Laurus Labs (+10.47%)** and **Biocon (+7.33%)** were the top performers, whereas **JB Chemicals (8.73%)** was the major laggard. As shown in the chart, the sector has given a breakout from an **Inverted Head and Shoulder formation**, pointing towards the trend reversal.

SECTORAL LOSER



With a loss of 2.21%, the **Realty sector** underperformed. Barring **Raymond (+14.88%)** and **Sobha (+4.33%)**, all the constituents ended the week in negative territory, with **Lodha (3.69%)** and **Prestige (3.17%)** being the major laggards. In the lower timeframe, the sector shows signs of a trend reversal, with a bullish pattern formation coupled with a hidden bullish divergence at the rounding bottom breakout zone, indicating a completed pullback. However, a confirmatory move is essential.

HIGHLIGHTS OF THE WEEK

30 June 2025-04 July 2025

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai—400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Neha Oza,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500.

Grievance Officer:

Email: grievancecell@progressiveshares.com